Luke Lee

Luke "Myung Sea" Lee serves as the Chief Executive Officer of NOBO Medicine and holds board positions at innocure therapeutics and Pharmascience. Previously, Luke was a Senior Strategy Advisor at Bertis Bioscience and the CEO of shaperon, where significant achievements included a KOSDAQ IPO and numerous licensing deals. Luke's prior experience includes leadership roles at Mundipharma, Abbott, and Eli Lilly, contributing to substantial sales growth, product launches, and strategic partnerships. Academic credentials include an MBA from The Wharton School, an MPH from Seoul National University, and an MD from Hallym University.